Systems Analysis Reveals Ageing-Related Perturbations in Retinoids and Sex Hormones in Alzheimer’s and Parkinson’s Diseases

Neurodegenerative diseases (NDDs), including Alzheimer’s (AD) and Parkinson’s diseases (PD), are complex heterogeneous diseases with highly variable patient responses to treatment. Due to the growing evidence for ageing-related clinical and pathological commonalities between AD and PD, these diseases have recently been studied in tandem. In this study, we analyse transcriptomic data from AD and PD patients, and stratify these patients into three subclasses with distinct gene expression and metabolic profiles. Through integrating transcriptomic data with a genome-scale metabolic model and validating our findings by network exploration and co-analysis using a zebrafish ageing model, we identify retinoids as a key ageing-related feature in all subclasses of AD and PD. We also demonstrate that the dysregulation of androgen metabolism by three different independent mechanisms is a source of heterogeneity in AD and PD. Taken together, our work highlights the need for stratification of AD/PD patients and development of personalised and precision medicine approaches based on the detailed characterisation of these subclasses.

[1]  J. Bayascas,et al.  Sex-Dependent Signatures, Time Frames and Longitudinal Fine-Tuning of the Marble Burying Test in Normal and AD-Pathological Aging Mice , 2021, Biomedicines.

[2]  J. Bayascas,et al.  Fine-Tuning the PI3K/Akt Signaling Pathway Intensity by Sex and Genotype-Load: Sex-Dependent Homozygotic Threshold for Somatic Growth but Feminization of Anxious Phenotype in Middle-Aged PDK1 K465E Knock-In and Heterozygous Mice , 2021, Biomedicines.

[3]  R. Goodacre,et al.  Metabolomics of sebum reveals lipid dysregulation in Parkinson’s disease , 2021, Nature Communications.

[4]  E. Vila,et al.  Sex-Dependent End-of-Life Mental and Vascular Scenarios for Compensatory Mechanisms in Mice with Normal and AD-Neurodegenerative Aging , 2021, Biomedicines.

[5]  R. DePinho,et al.  Telomeres: history, health, and hallmarks of aging , 2021, Cell.

[6]  M. Mayr,et al.  Systems biology in cardiovascular disease: a multiomics approach , 2020, Nature Reviews Cardiology.

[7]  Cory C. Funk,et al.  Metabolic Network Analysis Reveals Altered Bile Acid Synthesis and Metabolism in Alzheimer’s Disease , 2020, Cell reports. Medicine.

[8]  J. Nielsen,et al.  A systems biology approach for studying neurodegenerative diseases. , 2020, Drug discovery today.

[9]  J. Toldi,et al.  Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines , 2020, International journal of molecular sciences.

[10]  Jens Nielsen,et al.  Addressing the heterogeneity in liver diseases using biological networks , 2020, Briefings Bioinform..

[11]  E. Moro,et al.  Sex differences in movement disorders , 2020, Nature Reviews Neurology.

[12]  D. Aarsland,et al.  Postmortem Cortical Transcriptomics of Lewy Body Dementia Reveal Mitochondrial Dysfunction and Lack of Neuroinflammation. , 2020, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[13]  R. Sengoku Aging and Alzheimer's disease pathology , 2019, Neuropathology : official journal of the Japanese Society of Neuropathology.

[14]  Astrid Gall,et al.  Ensembl 2020 , 2019, Nucleic Acids Res..

[15]  S. Ray,et al.  Potential therapeutic roles of retinoids for prevention of neuroinflammation and neurodegeneration in Alzheimer’s disease , 2019, Neural regeneration research.

[16]  J. Nielsen,et al.  Systems biology perspective for studying the gut microbiota in human physiology and liver diseases , 2019, EBioMedicine.

[17]  D. Holtzman,et al.  Alzheimer Disease: An Update on Pathobiology and Treatment Strategies , 2019, Cell.

[18]  N. Fitz,et al.  Therapeutic targeting of nuclear receptors, liver X and retinoid X receptors, for Alzheimer's disease , 2019, British journal of pharmacology.

[19]  M. Ericsson,et al.  Female Sex and Brain-Selective Estrogen Benefit α-Synuclein Tetramerization and the PD-like Motor Syndrome in 3K Transgenic Mice , 2019, The Journal of Neuroscience.

[20]  Roeland M. H. Merks,et al.  Predicting Metabolism from Gene Expression in an Improved Whole-Genome Metabolic Network Model of Danio rerio , 2019, Zebrafish.

[21]  D. Shin,et al.  Association of statin use with Parkinson's disease: Dose–response relationship , 2019, Movement disorders : official journal of the Movement Disorder Society.

[22]  Gary D. Bader,et al.  A reference map of the human protein interactome , 2019, bioRxiv.

[23]  Akira Hasegawa,et al.  Update of the FANTOM web resource: expansion to provide additional transcriptome atlases , 2018, Nucleic Acids Res..

[24]  Vincent A. Traag,et al.  From Louvain to Leiden: guaranteeing well-connected communities , 2018, Scientific Reports.

[25]  R. Barker,et al.  The clinical heterogeneity of Parkinson's disease and its therapeutic implications , 2018, The European journal of neuroscience.

[26]  Leland McInnes,et al.  UMAP: Uniform Manifold Approximation and Projection , 2018, J. Open Source Softw..

[27]  Kevin R. Moon,et al.  Recovering Gene Interactions from Single-Cell Data Using Data Diffusion , 2018, Cell.

[28]  Charles C. White,et al.  A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer’s disease , 2018, Nature Neuroscience.

[29]  Hao Wang,et al.  RAVEN 2.0: A versatile toolbox for metabolic network reconstruction and a case study on Streptomyces coelicolor , 2018, bioRxiv.

[30]  J. Nielsen,et al.  Systems biology in hepatology: approaches and applications , 2018, Nature Reviews Gastroenterology & Hepatology.

[31]  E. Ruppin,et al.  Transcriptomic alterations during ageing reflect the shift from cancer to degenerative diseases in the elderly , 2018, Nature Communications.

[32]  S. Resnick,et al.  Testosterone Treatment and Cognitive Function in Older Men With Low Testosterone and Age-Associated Memory Impairment , 2017, JAMA.

[33]  Miguel Godinho Ferreira,et al.  Telomeres in aging and disease: lessons from zebrafish , 2016, Disease Models & Mechanisms.

[34]  Andrew D. Rouillard,et al.  Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..

[35]  Lior Pachter,et al.  Near-optimal probabilistic RNA-seq quantification , 2016, Nature Biotechnology.

[36]  R. Martins,et al.  The Effects of Testosterone Supplementation on Cognitive Functioning in Older Men , 2016, CNS & neurological disorders drug targets.

[37]  Philip R. Cohen,et al.  Topical Retinoids: Therapeutic Mechanisms in the Treatment of Photodamaged Skin , 2016, American Journal of Clinical Dermatology.

[38]  Daniel Marbach,et al.  Tissue-specific regulatory circuits reveal variable modular perturbations across complex diseases , 2016, Nature Methods.

[39]  J. Jankovic,et al.  Dopa-responsive dystonia—clinical and genetic heterogeneity , 2015, Nature Reviews Neurology.

[40]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[41]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[42]  Derek W Wright,et al.  Gateways to the FANTOM5 promoter level mammalian expression atlas , 2015, Genome Biology.

[43]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[44]  Cesare Furlanello,et al.  A promoter-level mammalian expression atlas , 2015 .

[45]  J. Nielsen,et al.  Identification of anticancer drugs for hepatocellular carcinoma through personalized genome‐scale metabolic modeling , 2014, Molecular systems biology.

[46]  M. Uhlén,et al.  Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease , 2014, Nature Communications.

[47]  L. Fazli,et al.  Androgen glucuronidation: an unexpected target for androgen deprivation therapy, with prognosis and diagnostic implications. , 2013, Cancer research.

[48]  M. Cayuela,et al.  Premature aging in telomerase-deficient zebrafish , 2013, Disease Models & Mechanisms.

[49]  Ellen T. Gelfand,et al.  The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.

[50]  Edward Y. Chen,et al.  Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool , 2013, BMC Bioinformatics.

[51]  I. Nookaew,et al.  Integration of clinical data with a genome-scale metabolic model of the human adipocyte , 2013, Molecular systems biology.

[52]  I. Nookaew,et al.  Enriching the gene set analysis of genome-wide data by incorporating directionality of gene expression and combining statistical hypotheses and methods , 2013, Nucleic acids research.

[53]  A. Jacinto,et al.  Telomerase Is Required for Zebrafish Lifespan , 2013, PLoS genetics.

[54]  K. Kitaoka,et al.  Tamibarotene: a candidate retinoid drug for Alzheimer's disease. , 2012, Biological & pharmaceutical bulletin.

[55]  Natapol Pornputtapong,et al.  Reconstruction of Genome-Scale Active Metabolic Networks for 69 Human Cell Types and 16 Cancer Types Using INIT , 2012, PLoS Comput. Biol..

[56]  Sudha Seshadri,et al.  Inverse association between cancer and Alzheimer’s disease: results from the Framingham Heart Study , 2012, BMJ : British Medical Journal.

[57]  D. Selkoe,et al.  Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. , 2011, Archives of neurology.

[58]  Matko Bosnjak,et al.  REVIGO Summarizes and Visualizes Long Lists of Gene Ontology Terms , 2011, PloS one.

[59]  Manuel B. Graeber,et al.  PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease , 2010, Science Translational Medicine.

[60]  Matthew D. Wilkerson,et al.  ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking , 2010, Bioinform..

[61]  J. Hindle,et al.  Ageing, neurodegeneration and Parkinson's disease. , 2010, Age and ageing.

[62]  E. Schernhammer,et al.  Parkinson’s disease and cancer risk: a systematic review and meta-analysis , 2010, Cancer Causes & Control.

[63]  K. Shudo,et al.  Towards Retinoid Therapy for Alzheimer’s Disease , 2009, Current Alzheimer research.

[64]  D. Stephan,et al.  Genetic control of human brain transcript expression in Alzheimer disease. , 2009, American journal of human genetics.

[65]  J. Wands,et al.  Alzheimer's Disease is Type 3 Diabetes—Evidence Reviewed , 2008, Journal of diabetes science and technology.

[66]  D. Stephan,et al.  A survey of genetic human cortical gene expression , 2007, Nature Genetics.

[67]  M. Stampfer,et al.  Cardiovascular disease and Alzheimer's disease: common links , 2006, Journal of internal medicine.

[68]  Rune Blomhoff,et al.  Overview of retinoid metabolism and function. , 2006, Journal of neurobiology.

[69]  F. Middleton,et al.  Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[70]  L. Baum Sex, hormones, and Alzheimer's disease. , 2005, The journals of gerontology. Series A, Biological sciences and medical sciences.

[71]  J. Nielsen,et al.  Uncovering transcriptional regulation of metabolism by using metabolic network topology. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[72]  M. Memo,et al.  Lewy-body dementia and responsiveness to cholinesterase inhibitors: a paradigm for heterogeneity of Alzheimer's disease? , 1996, Trends in pharmacological sciences.

[73]  C. Martucci The role of 2-methoxyestrone in estrogen action. , 1983, Journal of steroid biochemistry.

[74]  Geoffrey E. Hinton,et al.  Visualizing Data using t-SNE , 2008 .